Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation.
A 36-year-old man underwent an allogeneic BMT for acute lymphoblastic leukemia. Eighteen days later the patient developed sudden onset of painful, gross hematuria due to adenovirus type 11 infection that did not respond to conservative therapy. There was an increase in serum creatinine levels and delayed recovery of the platelet count, associated with hemophagocytosis. After obtaining informed consent, vidarabine, which has been shown to be active against adenovirus in vitro, was started. The patient's symptoms improved within a few days of vidarabine therapy and urine cultures for adenovirus became negative. No serious adverse effects were observed. Vidarabine may be one therapeutic option in life-threatening adenovirus infection.
Kitabayashi
A
A
Department of Internal Medicine, Akita University School of Medicine, Japan.
Hirokawa
M
M
Kuroki
J
J
Nishinari
T
T
Niitsu
H
H
Miura
A B
AB
D000258:Adenovirus Infections, Human / Q000188:drug therapy* / Q000209:etiology*; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology*; D006417:Hematuria / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000627:therapeutic use*
D014740:Vidarabine